Mode
Text Size
Log in / Sign up
N/A N=160 Randomized Triple-blind Treatment

Success Rate of 4 Injection Protocols for Mandibular First Molars With Symptomatic Irreversible Pulpitis

Root Canal Infection

Enrolled (actual)
160
Serious AEs
0.0%
Results posted
Oct 2021
Primary outcome: Primary: Number of Participants With Successful Injection Technique Assessed by Verbal Rating Scale (VRS) — 16; 37; 29; 26 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
local anesthesia (Procedure)
Age
Adult · 21+ yrs
Sex
All
Sponsor
Ain Shams University
Primary completion
May 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Successful Injection Technique Assessed by Verbal Rating Scale (VRS)
16; 37; 29; 26
SECONDARY
Changes in the Heart Rate Before, During and After the Injection
72; 72; 71; 71; 71; 72

Summary

Achieving profound anesthesia during endodontic treatment of mandibular molars with symptomatic irreversible pulpitis is still a demanding clinical challenge. therefore, the success Rate of 4 Injection protocols for Mandibular First Molars with Symptomatic Irreversible Pulpitis was evaluated clinically in a randomized triple-blind trial

Eligibility Criteria

Inclusion Criteria

  • Patients included in the study were healthy males and females
  • (Category: American Society of Anesthesiologists class 1)
  • aged 21-49 years
  • with no physical disability, facial paresthesia or psychological problems
  • presenting with a single vital mature mandibular first molar, with signs and/or symptoms of symptomatic irreversible pulpitis

Exclusion Criteria

  • Pregnant women
  • patients who took analgesics or other medications that would alter the inflammatory response of the pulp or provide analgesia 6- hours pre-operatively
  • those with known sensitivity to the pharmaceuticals used in this trial.
  • those with pathological periodontal pockets
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04929522). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search